Truncated N(6)-substituted-4'-oxo- and 4'-thioadenosine derivatives with C2 or C8 substitution were studied as dual acting A(2A) and A(3) adenosine receptor (AR) ligands. The lithiation-mediated stannyl transfer and palladium-catalyzed cross-coupling reactions were utilized for functionalization of the C2 position of 6-chloropurine nucleosides. An unsubstituted 6-amino group and a hydrophobic C2 substituent were required for high affinity at the hA(2A)AR, but hydrophobic C8 substitution abolished binding at the hA(2A)AR. However, most of synthesized compounds displayed medium to high binding affinity at the hA(3)AR, regardless of C2 or C8 substitution, and low efficacy in a functional cAMP assay. Several compounds tended to be full hA(2A)AR agonists. C2 substitution probed geometrically through hA(2A)AR docking was important for binding in order of hexynyl > hexenyl > hexanyl. Compound 4g was the most potent ligand acting dually as hA(2A)AR agonist and hA(3)AR antagonist, which might be useful for treatment of asthma or other inflammatory diseases.
Truncated N(6)-substituted-4'-oxo- and 4'-thioadenosine derivatives with n class="Chemical">C2 or C8 substitution were studied as dual acting A(2A) and A(3) adenosine receptor (AR) ligands. The lithiation-mediated stannyl transfer and palladium-catalyzed cross-coupling reactions were utilized for functionalization of the C2 position of 6-chloropurine nucleosides. An unsubstituted 6-amino group and a hydrophobic C2 substituent were required for high affinity at the hA(2A)AR, but hydrophobic C8 substitution abolished binding at the hA(2A)AR. However, most of synthesized compounds displayed medium to high binding affinity at the hA(3)AR, regardless of C2 or C8 substitution, and low efficacy in a functional cAMP assay. Several compounds tended to be full hA(2A)AR agonists. C2 substitution probed geometrically through hA(2A)AR docking was important for binding in order of hexynyl > hexenyl > hexanyl. Compound 4g was the most potent ligand acting dually as hA(2A)AR agonist and hA(3)AR antagonist, which might be useful for treatment of asthma or other inflammatory diseases.
Authors: Veli-Pekka Jaakola; Mark T Griffith; Michael A Hanson; Vadim Cherezov; Ellen Y T Chien; J Robert Lane; Adriaan P Ijzerman; Raymond C Stevens Journal: Science Date: 2008-10-02 Impact factor: 47.728
Authors: Jinha Yu; Philip Mannes; Young-Hwan Jung; Antonella Ciancetta; Amelia Bitant; David I Lieberman; Sami Khaznadar; John A Auchampach; Zhan-Guo Gao; Kenneth A Jacobson Journal: Medchemcomm Date: 2018-10-18 Impact factor: 3.597
Authors: Silvia Paoletta; Dilip K Tosh; Amanda Finley; Elizabeth T Gizewski; Steven M Moss; Zhan-Guo Gao; John A Auchampach; Daniela Salvemini; Kenneth A Jacobson Journal: J Med Chem Date: 2013-07-03 Impact factor: 7.446
Authors: Eleonora Spinozzi; Cecilia Baldassarri; Laura Acquaticci; Fabio Del Bello; Mario Grifantini; Loredana Cappellacci; Petrelli Riccardo Journal: Med Chem Res Date: 2021-01-25 Impact factor: 2.351
Authors: Francisco Z Valdés; Víctor Z Luna; Bárbara R Arévalo; Nelson V Brown; Margarita C Gutiérrez Journal: Mini Rev Med Chem Date: 2018 Impact factor: 3.862